For optimal results, CJC-1295 is typically administered via subcutaneous injection. It is recommended to follow a dosing schedule as directed by a healthcare professional.
Semaglutide is typically administered as a subcutaneous injection (under the skin) and is taken once a week. It mimics the GLP-1 hormone in the body, which increases insulin secretion, slows gastric emptying, and helps with appetite control.
Sermorelin is administered through subcutaneous injections, typically at night to align with the body’s natural growth hormone production during sleep. The exact dosage and duration depend on individual health goals and should be prescribed by a healthcare provider.
Tesamorelin is administered as a subcutaneous injection (under the skin), typically once a day. It works by acting as a growth hormone-releasing hormone (GHRH) analog, which stimulates the pituitary gland to release growth hormone, leading to a reduction in visceral fat.
Tirzepatide is administered as a weekly subcutaneous injection (under the skin). It acts as both a GLP-1 and GIP receptor agonist, which means it increases insulin release, reduces glucagon production, slows down stomach emptying, and enhances the feeling of fullness.